Guffanti, F.
Alvisi, M F
Anastasia, A.
Ricci, F.
Chiappa, M.
Llop-Guevara, A.
Serra, V. http://orcid.org/0000-0001-6620-1065
Fruscio, R.
Degasperi, A. http://orcid.org/0000-0001-6879-0596
Nik-Zainal, S.
Bani, M R
Lupia, M.
Giavazzi, R.
Rulli, E.
Damia, G. http://orcid.org/0000-0001-9749-434X
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG ID19797, IG ID23520)
Fundación Científica Asociación Española Contra el Cáncer (INVES20095LLOP)
"la Caixa" Foundation (LCF/TR/CC19/52470003)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CPII19/00033)
Article History
Received: 7 June 2021
Revised: 7 October 2021
Accepted: 21 October 2021
First Online: 3 November 2021
Change Date: 16 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-023-02205-1
Competing interests
: VS reports grants from AstraZeneca, Tesaro and personal fees from Abbvie, outside the submitted work. In addition, AL-G and VS have a patent WO2019122411A1 pending. The other authors declare no competing interests.
: All animal experiments were approved by the Ethical Committee of the Mario Negri Institute for Pharmacological Research IRCCS and the Italian Ministry of Health (approval numbers 510-2016 and 296/2018-PR).
: Not applicable.